Searchable abstracts of presentations at key conferences in endocrinology

ea0034p122 | Clinical practice/governance and case reports | SFEBES2014

Mitotane ameliorates testostoxicosis due to metastatic Leydig cell tumour

Johal Nicholas , Cullen Michael , Guest Peter , Porfiri Emilio , Arlt Wiebke

Leydig cell tumour (LCT) is a stromal testicular tumour comprising 3% of testicular neoplasms. Metastases are rare, have a poor prognosis and can appear many years after tumour removal. Current therapy for metastatic disease is limited, with no role for radiotherapy and poor efficacy of chemotherapy regimens. About 50–70% of metastatic LCT show associated steroid excess, comprising not only androgens but sometimes steroids physiologically produced in the adrenals. Here we...

ea0037ep1145 | Endocrine tumours | ECE2015

Mitotane treatment for metastatic Leydig cell tumour

Chortis Vasileios , Johal Nicholas , Cullen Michael , Bancos Irina , Guest Peter , Porfiri Emilio , Arlt Wiebke

Introduction: Testicular leydig cell tumours (LCTs) are rare stromal tumors often associated with androgen excess. Metastatic malignant LCTs typically show resistance to radiotherapy and cytotoxic chemotherapy, calling for alternative management options. Here we describe our experience with treatment of two patients with metastatic LCTs with the adrenolytic drug Mitotane.Patients/methods: Case 1: A 51-year-old patient presented with a 6 month hi...